Sonder Capital Closes Second Fund Futures II to Transform Patient Care
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Source: Newsfilter
- Fund Size and Investors: Sonder Capital announced the successful closing of its second fund, Futures II, with participation from Mayo Clinic and Sutter Health, reflecting a strong interest in innovative healthcare technologies that are expected to advance the future of patient care.
- Investment Focus and Goals: The fund is anchored in AI-enabled medical robotics and minimally invasive therapies, aiming to support companies that create entirely new care pathways and business models, thereby enhancing accessibility and quality of healthcare services.
- Technological Innovation and Impact: The introduction of medical robotics has already transformed operating room procedures, and the addition of AI is set to unlock new levels of performance and automation across care pathways, accelerating a revolution in healthcare systems worldwide that will benefit patients and clinicians alike.
- Team Background and Success Stories: Sonder Capital's team consists of seasoned investors and innovators who have successfully supported numerous companies that have transformed the healthcare industry, including Intuitive Surgical and Shockwave Medical, showcasing their deep expertise in healthcare investment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 402.300
Low
575.00
Averages
637.32
High
740.00
Current: 402.300
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical Stock Sees Modest Gain
- Stock Performance: Intuitive Surgical, Inc. ended the recent trading session at $407.29, reflecting a 1.24% increase, outperforming the S&P 500's 0.74% loss, indicating its resilience amid broader market declines.
- Earnings Expectations: The upcoming earnings report is projected to show an EPS of $2.48, a 13.24% increase year-over-year, with revenue expected to reach $2.81 billion, marking a 15% rise, highlighting the company's sustained growth potential in the medical device sector.
- Analyst Ratings: Currently holding a Zacks Rank of #2 (Buy), Intuitive Surgical reflects analysts' optimistic outlook on its business health and profitability, with a recent 0.05% increase in EPS estimates indicating confidence in its future performance.
- Valuation Analysis: The company is trading at a forward P/E ratio of 38.68, significantly above the industry average of 21.61, suggesting that while it commands a premium, investors should carefully assess its valuation relative to growth prospects to gauge investment risk and return.
See More
Investment Insights on Intuitive Surgical
- Market Trend Analysis: In the latest Motley Fool Scoreboard episode, analysts discussed market trends for Intuitive Surgical, noting that while the company did not make the recommended top 10 stocks list, it still attracts investor interest, reflecting its potential in the medical technology sector.
- Investment Return Comparison: The Motley Fool Stock Advisor boasts an average return of 983%, significantly outperforming the S&P 500's 212%, indicating that even though Intuitive Surgical is not recommended, its market performance remains noteworthy, prompting investors to carefully assess its future growth potential.
- AI and Market Outlook: The episode highlighted the potential for AI to create the world's first trillionaire, suggesting opportunities for Intuitive Surgical in the intersection of medical technology and AI, which investors should monitor for innovation and development.
- Investor Community Engagement: Motley Fool encourages investors to join its community to share investment experiences and gain the latest market insights, and although Intuitive Surgical is not on the recommended list, its technology and market position continue to spark widespread discussion.
See More
Market Trends and Investment Insights on Intuitive Surgical
- Market Trend Insights: The latest Motley Fool Scoreboard episode features expert analysis on Intuitive Surgical's market dynamics, providing deep insights into future investment opportunities that help investors grasp industry developments.
- Investment Opportunity Assessment: The discussion highlights potential investment opportunities in Intuitive Surgical, emphasizing its innovation capabilities and market leadership in the medical device sector, which could yield substantial returns for investors.
- Stock Price Reference: The stock prices mentioned in the episode are from April 22, 2026, reflecting market expectations for Intuitive Surgical's future performance, prompting investors to monitor stock price fluctuations in relation to industry trends.
- Expert Opinion Sharing: Through the video content, experts share in-depth analyses of Intuitive Surgical, helping viewers understand the company's strategic positioning in medical technology and its appeal to investors.
See More
Investment Opportunities in Healthcare Stocks
- Intuitive Surgical Outlook: Despite a 25% drop in share price this year, Intuitive Surgical's financial performance remains robust, with revenue and procedures growing healthily in Q1, indicating its leadership in the robotic-assisted surgery market and long-term growth potential.
- HCA Healthcare's Market Position: HCA Healthcare's stock has declined 21% year-to-date, yet its extensive medical network and strong relationships with patients and physicians position it well to benefit from the aging population trend, making it an attractive investment.
- Abbott Laboratories' Innovation: While Abbott Laboratories' nutrition and diagnostics segments have hindered sales growth, its core medical device unit remains strong, particularly in structural heart products and diabetes care, which are expected to drive long-term growth.
- Dividend King's Appeal: Abbott Laboratories has increased its dividends for 54 consecutive years, earning the title of Dividend King, showcasing its stable income potential and long-term investment value, appealing to income-seeking investors.
See More
Investment Opportunities in the Healthcare Sector
- Market Challenges and Opportunities: Despite a challenging macroeconomic environment, Intuitive Surgical's stock has fallen 25% this year; however, its financial performance remains strong, with revenue and procedures growing healthily in Q1, indicating its leadership in the robotic-assisted surgery market and long-term growth potential.
- Resilience of HCA Healthcare: HCA Healthcare's stock has declined 21% year-to-date due to high cost pressures, yet its extensive medical network across the U.S. and strong relationships with patients and physicians position the company to benefit from long-term trends like an aging population, making it a worthwhile long-term hold.
- Strength of Abbott's Core Business: Although Abbott's nutrition and diagnostics segments have hindered sales growth, its core medical device division remains robust, particularly in structural heart products and diabetes care, which are expected to drive future growth.
- Attractiveness of Dividend King: Abbott has increased its dividends for 54 consecutive years, earning the title of 'Dividend King'; its stable dividend history and innovation capabilities make it a strong investment option for those seeking consistent income over the long term.
See More
Intuitive Surgical's 30% Stock Drop May Present a Rare Buying Opportunity
- Market Performance Review: Intuitive Surgical's stock has declined approximately 30% since the beginning of 2026; however, the number of da Vinci surgical systems installed globally has increased by 12% year-over-year, indicating sustained demand and growth potential in the surgical robotics market.
- Surgical Demand Growth: The number of procedures performed using the da Vinci system has risen by 17% year-over-year, demonstrating strong patient demand for robotic surgery, which further solidifies the company's market position and future revenue expectations.
- Diversified Revenue Sources: Intuitive Surgical generates about 25% of its revenue from da Vinci system sales, with the remainder coming from parts and services, creating a stable revenue stream that enhances the business's resilience amid growing demand for surgical robots.
- Investor Confidence Test: Despite the significant stock price drop, Intuitive Surgical's fundamentals remain strong, and historical data shows that the company's stock typically recovers and reaches new highs after similar pullbacks, attracting attention from more aggressive growth investors.
See More
Intuitive Surgical Stock Sees Modest Gain
- Stock Performance: Intuitive Surgical, Inc. ended the recent trading session at $407.29, reflecting a 1.24% increase, outperforming the S&P 500's 0.74% loss, indicating its resilience amid broader market declines.
- Earnings Expectations: The upcoming earnings report is projected to show an EPS of $2.48, a 13.24% increase year-over-year, with revenue expected to reach $2.81 billion, marking a 15% rise, highlighting the company's sustained growth potential in the medical device sector.
- Analyst Ratings: Currently holding a Zacks Rank of #2 (Buy), Intuitive Surgical reflects analysts' optimistic outlook on its business health and profitability, with a recent 0.05% increase in EPS estimates indicating confidence in its future performance.
- Valuation Analysis: The company is trading at a forward P/E ratio of 38.68, significantly above the industry average of 21.61, suggesting that while it commands a premium, investors should carefully assess its valuation relative to growth prospects to gauge investment risk and return.
See More
Investment Insights on Intuitive Surgical
- Market Trend Analysis: In the latest Motley Fool Scoreboard episode, analysts discussed market trends for Intuitive Surgical, noting that while the company did not make the recommended top 10 stocks list, it still attracts investor interest, reflecting its potential in the medical technology sector.
- Investment Return Comparison: The Motley Fool Stock Advisor boasts an average return of 983%, significantly outperforming the S&P 500's 212%, indicating that even though Intuitive Surgical is not recommended, its market performance remains noteworthy, prompting investors to carefully assess its future growth potential.
- AI and Market Outlook: The episode highlighted the potential for AI to create the world's first trillionaire, suggesting opportunities for Intuitive Surgical in the intersection of medical technology and AI, which investors should monitor for innovation and development.
- Investor Community Engagement: Motley Fool encourages investors to join its community to share investment experiences and gain the latest market insights, and although Intuitive Surgical is not on the recommended list, its technology and market position continue to spark widespread discussion.
See More
Market Trends and Investment Insights on Intuitive Surgical
- Market Trend Insights: The latest Motley Fool Scoreboard episode features expert analysis on Intuitive Surgical's market dynamics, providing deep insights into future investment opportunities that help investors grasp industry developments.
- Investment Opportunity Assessment: The discussion highlights potential investment opportunities in Intuitive Surgical, emphasizing its innovation capabilities and market leadership in the medical device sector, which could yield substantial returns for investors.
- Stock Price Reference: The stock prices mentioned in the episode are from April 22, 2026, reflecting market expectations for Intuitive Surgical's future performance, prompting investors to monitor stock price fluctuations in relation to industry trends.
- Expert Opinion Sharing: Through the video content, experts share in-depth analyses of Intuitive Surgical, helping viewers understand the company's strategic positioning in medical technology and its appeal to investors.
See More
Investment Opportunities in Healthcare Stocks
- Intuitive Surgical Outlook: Despite a 25% drop in share price this year, Intuitive Surgical's financial performance remains robust, with revenue and procedures growing healthily in Q1, indicating its leadership in the robotic-assisted surgery market and long-term growth potential.
- HCA Healthcare's Market Position: HCA Healthcare's stock has declined 21% year-to-date, yet its extensive medical network and strong relationships with patients and physicians position it well to benefit from the aging population trend, making it an attractive investment.
- Abbott Laboratories' Innovation: While Abbott Laboratories' nutrition and diagnostics segments have hindered sales growth, its core medical device unit remains strong, particularly in structural heart products and diabetes care, which are expected to drive long-term growth.
- Dividend King's Appeal: Abbott Laboratories has increased its dividends for 54 consecutive years, earning the title of Dividend King, showcasing its stable income potential and long-term investment value, appealing to income-seeking investors.
See More
Investment Opportunities in the Healthcare Sector
- Market Challenges and Opportunities: Despite a challenging macroeconomic environment, Intuitive Surgical's stock has fallen 25% this year; however, its financial performance remains strong, with revenue and procedures growing healthily in Q1, indicating its leadership in the robotic-assisted surgery market and long-term growth potential.
- Resilience of HCA Healthcare: HCA Healthcare's stock has declined 21% year-to-date due to high cost pressures, yet its extensive medical network across the U.S. and strong relationships with patients and physicians position the company to benefit from long-term trends like an aging population, making it a worthwhile long-term hold.
- Strength of Abbott's Core Business: Although Abbott's nutrition and diagnostics segments have hindered sales growth, its core medical device division remains robust, particularly in structural heart products and diabetes care, which are expected to drive future growth.
- Attractiveness of Dividend King: Abbott has increased its dividends for 54 consecutive years, earning the title of 'Dividend King'; its stable dividend history and innovation capabilities make it a strong investment option for those seeking consistent income over the long term.
See More
Intuitive Surgical's 30% Stock Drop May Present a Rare Buying Opportunity
- Market Performance Review: Intuitive Surgical's stock has declined approximately 30% since the beginning of 2026; however, the number of da Vinci surgical systems installed globally has increased by 12% year-over-year, indicating sustained demand and growth potential in the surgical robotics market.
- Surgical Demand Growth: The number of procedures performed using the da Vinci system has risen by 17% year-over-year, demonstrating strong patient demand for robotic surgery, which further solidifies the company's market position and future revenue expectations.
- Diversified Revenue Sources: Intuitive Surgical generates about 25% of its revenue from da Vinci system sales, with the remainder coming from parts and services, creating a stable revenue stream that enhances the business's resilience amid growing demand for surgical robots.
- Investor Confidence Test: Despite the significant stock price drop, Intuitive Surgical's fundamentals remain strong, and historical data shows that the company's stock typically recovers and reaches new highs after similar pullbacks, attracting attention from more aggressive growth investors.
See More
